Q-omics provides the consensus-scored MIR1266 profile across patient tissues and cancer cell-line models. MIR1266 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR1266 is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, MIR1266 RNA expression shows 6,937 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, CHOL, and ESCA as cancer lineages where MIR1266 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1266 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1266 survival associations across molecular data types. MIR1266 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1266 RNA expression–survival associations across cancer types. High MIR1266 expression shows unfavorable associations in MESO, THCA, KIRC, BLCA and LGG, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR1266 RNA expression.
This table summarizes MIR1266 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1266. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1266 shows higher tumor expression in CHOL and STAD. The CHOL box plot shows higher MIR1266 RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with MIR1266 in patient tissues and cancer cell lines. In patient samples, MIR1266 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
